TY - JOUR
T1 - Metabolic profiling of serum in patients with cartilage tumours using 1H-NMR spectroscopy
T2 - A pilot study
AU - López-Garrido, Liliana
AU - Bañuelos-Hernández, Angel E.
AU - Pérez-Hernández, Elizabeth
AU - Tecualt-Gómez, Romeo
AU - Quiroz-Williams, Jorge
AU - Ariza-Castolo, Armando
AU - Becerra-Martínez, Elvia
AU - Pérez-Hernández, Nury
N1 - Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Cartilage-forming lesions include tumours that can vary in severity from benign enchondromas to high-grade malignant chondrosarcomas. Chondrosarcoma is the second most frequent malignant bone tumour, accounting for 20–30% of all malignant bone neoplasms. Surgery is the standard treatment for cartilage tumours (CTs); however, their incidental diagnosis and the difficult differentiation of low-grade lesions like chondrosarcoma grade I from benign entities like enchondroma are challenges for clinical management. In this sense, the search for circulating biomarkers for early detection and prognosis is an ongoing interest. Targeted metabolomics is a powerful tool that can propose potential biomarkers in biological fluids as well as help to discover disturbed metabolic pathways to reveal tumour pathogenesis. In this context, the aim of this study was to investigate the 1H nuclear magnetic resonance metabolomic serum profile of patients with CTs contrasted with healthy controls. Forty-one metabolites were identified and quantified; the multivariate statistical methods principal component analysis and partial least squares discriminant analysis reveal a clear separation of the CT group, that is, the differential metabolites that were involved in two main metabolic pathways: the taurine and hypotaurine metabolism and synthesis and degradation of ketone bodies. Our results represent preliminary work for emergent serum-based diagnostics or prognostic methods for patients with chondrogenic tumours.
AB - Cartilage-forming lesions include tumours that can vary in severity from benign enchondromas to high-grade malignant chondrosarcomas. Chondrosarcoma is the second most frequent malignant bone tumour, accounting for 20–30% of all malignant bone neoplasms. Surgery is the standard treatment for cartilage tumours (CTs); however, their incidental diagnosis and the difficult differentiation of low-grade lesions like chondrosarcoma grade I from benign entities like enchondroma are challenges for clinical management. In this sense, the search for circulating biomarkers for early detection and prognosis is an ongoing interest. Targeted metabolomics is a powerful tool that can propose potential biomarkers in biological fluids as well as help to discover disturbed metabolic pathways to reveal tumour pathogenesis. In this context, the aim of this study was to investigate the 1H nuclear magnetic resonance metabolomic serum profile of patients with CTs contrasted with healthy controls. Forty-one metabolites were identified and quantified; the multivariate statistical methods principal component analysis and partial least squares discriminant analysis reveal a clear separation of the CT group, that is, the differential metabolites that were involved in two main metabolic pathways: the taurine and hypotaurine metabolism and synthesis and degradation of ketone bodies. Our results represent preliminary work for emergent serum-based diagnostics or prognostic methods for patients with chondrogenic tumours.
KW - H NMR
KW - cartilage tumours
KW - metabolic profiling
KW - multivariate analysis
KW - serum
UR - http://www.scopus.com/inward/record.url?scp=85070709330&partnerID=8YFLogxK
U2 - 10.1002/mrc.4925
DO - 10.1002/mrc.4925
M3 - Artículo
C2 - 31323132
SN - 0749-1581
VL - 58
SP - 65
EP - 76
JO - Magnetic Resonance in Chemistry
JF - Magnetic Resonance in Chemistry
IS - 1
ER -